Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Cancer Treatment Reviews

• Publication date

  2010-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ctrv.2010.03.001PMID 20347527
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Peritoneal carcinomatosis immunotherapy with the trifunctional anti-EpCAM x anti-CD3 antibody catumaxomab in patients with colon, gastric, or pancreatic cancer: Long-term results after a 2-year follow-up.

  2016cited by this paper
• Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer.

  2009cited by this paper
• Elimination of cancer stem cells (CD133+/EpCAM+) from malignant ascites by the trifunctional antibody catumaxomab: Results from a pivotal phase II/III study.

  2009cited by this paper
• Bispecific antibodies for cancer therapy

  2009cited by this paper
• Nuclear signalling by tumour-associated antigen EpCAM

  2009cited by this paper
• Bispecific antibodies for cancer therapy: the light at the end of the tunnel?

  2009cited by this paper
• Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis

  2009cited by this paper
• Clinical benefit of catumaxomab in malignant ascites in patient subpopulations in a pivotal phase II/III trial.

  2009cited by this paper
• Safety of catumaxomab: Cytokine-release-related symptoms as a possible predictive factor for efficacy in a pivotal phase II/III trial in malignant ascites.

  2009cited by this paper
• Decrease of VEGF within malignant ascites during catumaxomab treatment: Results from a pivotal phase II/III study.

  2009cited by this paper
• Test System for Trifunctional Antibodies in 3D MCTS Culture

  2009cited by this paper
• 6507 Catumaxomab treatment in gastric-cancer patients with malignant ascites – subgroup-analysis of a pivotal trial

  2009cited by this paper
• Intraperitoneal treatment of malignant ascites due to epithelial tumors with catumaxomab: A phase II/III study

  2008cited by this paper
• Identification and expansion of the tumorigenic lung cancer stem cell population

  2008cited by this paper
• Intraoperative, adjuvant treatment of gastric cancer with the trifunctional antibody catumaxomab compared to surgery alone: A phase II study

  2008cited by this paper
• Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctional bispecific antibody.

  2008cited by this paper
• Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3.

  2008cited by this paper
• Intraoperative Immuntherapie mit dem trifunktionalen Antikörper Catumaxomab bei Patienten mit fortgeschrittenem Magen-, Colon- und Pankreaskarzinom: Ergebnisse einer Phase I Pilotstudie

  2008cited by this paper
• Identification and expansion of human colon-cancer-initiating cells

  2007cited by this paper
• Adoptive therapy of head and neck squamous cell carcinoma with antibody coated immune cells: a pilot clinical trial

  2007cited by this paper
• Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer

  2007cited by this paper
• EpCAM (CD326) finding its role in cancer

  2007cited by this paper
• A human colon cancer cell capable of initiating tumour growth in immunodeficient mice

  2007cited by this paper
• Effective Relief of Malignant Ascites in Patients with Advanced Ovarian Cancer by a Trifunctional Anti-EpCAM × Anti-CD3 Antibody: A Phase I/II Study

  2007cited by this paper
• Pattern and prognostic factors in patients with malignant ascites: a retrospective study.

  2007cited by this paper
• The pathogenesis of malignant ascites.

  2007cited by this paper
• Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule.

  2007cited by this paper
• A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects.

  2007cited by this paper
• Randomized, multicenter, two-dose level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM x anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients

  2007cited by this paper
• 5005 ORAL Randomized, multicenter, 2-dose-level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM × anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients

  2007cited by this paper
• Treatment of ovarian cancer patients with malignant ascites using the trifunctional antibody catumaxomab: Results of a phase II/III study

  2007cited by this paper
• Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer.

  2007cited by this paper
• Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers

  2006cited by this paper
• Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer.

  2006cited by this paper
• Efficacy of intraperitoneal treatment with the trifunctional antibody catumaxomab in patients with GI-tract cancer and peritoneal carcinomatosis: A matched-pair analysis.

  2006cited by this paper
• Malignant ascites: systematic review and guideline for treatment.

  2006cited by this paper
• Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies

  2006cited by this paper
• Ep-CAM expression in squamous cell carcinoma of the esophagus: a potential therapeutic target and prognostic marker

  2006cited by this paper
• Serial killing of tumor cells by cytotoxic T cells redirected with a CD19‐/CD3‐bispecific single‐chain antibody construct

  2005cited by this paper
• Evaluation of a Panel of Molecular Markers for the Diagnosis of Malignant Serous Effusions

  2005cited by this paper
• Treatment of peritoneal carcinomatosis due to GI-tract cancer by intraperitoneal application of the trifunctional antibody catumaxomab (anti-EpcAM x anti-CD3): Results of a phase I/II trial

  2005cited by this paper
• Peritoneal inflammation – A microenvironment for Epithelial Ovarian Cancer (EOC)

  2004cited by this paper
• High Ep-CAM Expression is Associated with Poor Prognosis in Node-positive Breast Cancer

  2004cited by this paper
• Frequent EpCam protein expression in human carcinomas.

  2004cited by this paper
• Opsonization with a trifunctional bispecific (alphaCD3 x alphaEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes.

  2004cited by this paper
• Immunotherapy with the trifunctional antibody removab leads to significant elimination of tumor cells from malignant ascites in ovarian cancer: Results of a phase I/II study.

  2004cited by this paper
• The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation

  2004cited by this paper
• Malignant ascites: past, present, and future.

  2004cited by this paper
• Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

  2004cited by this paper
• Antitumour effects of a bispecific trivalent antibody in multicellular tumour spheroids.

  2004cited by this paper
• Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice.

  2004cited by this paper
• Human antiglobulin response to foreign antibodies: therapeutic benefit?

  2003cited by this paper
• Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid

  2003cited by this paper
• Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors.

  2003cited by this paper
• The current and future management of malignant ascites.

  2003cited by this paper
• Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study.

  2002cited by this paper
• Intraperitoneal bispecific antibody (HEA125xOKT3) therapy inhibits malignant ascites production in advanced ovarian carcinoma

  2002cited by this paper
• Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3).

  2001cited by this paper
• TNFalpha contributes to the antitumor activity of a bispecific, trifunctional antibody.

  2001cited by this paper
• Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody.

  2001cited by this paper
• Epidermal Growth Factor-Like Repeats Mediate Lateral and Reciprocal Interactions of Ep-CAM Molecules in Homophilic Adhesions

  2001cited by this paper
• Lysis of Prostate Carcinoma Cells by Trifunctional Bispecific Antibodies (αEpCAM × αCD3)

  2001cited by this paper
• CD3 directed bispecific antibodies induce increased lymphocyte–endothelial cell interactions in vitro

  2000cited by this paper
• The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells

  2000cited by this paper
• The biology of the 17–1A antigen (Ep-CAM)

  1999cited by this paper
• Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies

  1999cited by this paper
• Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing.

  1999cited by this paper
• Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial.

  1998cited by this paper
• Malignant ascites: a 2-year review from a teaching hospital.

  1996cited by this paper
• Malignant ascites

  1996cited by this paper
• Malignant ascites: demographics, therapeutic efficacy and predictors of survival.

  1996cited by this paper
• Normal Human Immune Peritoneal Cells: Subpopulations and Functional Characteristics

  1996cited by this paper
• Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation.

  1995cited by this paper
• Pathogenesis of ascites tumor growth: angiogenesis, vascular remodeling, and stroma formation in the peritoneal lining.

  1995cited by this paper
• Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies.

  1995cited by this paper
• Comparison of antigen expression on fresh and cultured ascites cells and on solid tumors of patients with epithelial ovarian cancer

  1994cited by this paper
• Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule

  1994cited by this paper
• Comparison of antigen expression on fresh and cultured ascites cells and on solid tumors of patients with epithelial ovarian cancer.

  1993cited by this paper
• Utility of BER‐EP4 in the diagnosis of adenocarcinoma in effusions: An immunocytochemical study of 232 cases

  1993cited by this paper
• General aspects of cytokine-release syndrome: timing and incidence of symptoms.

  1993cited by this paper
• Immunocytochemical Staining of Serous Effusions With the Monoclonal Antibody Ber‐Ep4

  1992cited by this paper
• Analysis of antigen expression at multiple tumor sites in epithelial ovarian cancer.

  1991cited by this paper
• A longitudinal study of antigen expression in epithelial ovarian cancer.

  1989cited by this paper
• The tumor-associated antigens BR55-2, GA73-3 and GICA 19-9 in normal and corresponding neoplastic human tissues, especially gastrointestinal tissues.

  1989cited by this paper
• Hybrid antibodies can target sites for attack by T cells

  1985cited by this paper
• Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies.

  1979cited by this paper

• Preclinical Evaluation of AHT-102, a CLDN18.2 × CD3 Bispecific Antibody: Pharmacokinetics, Anti-Tumor Efficacy, Tissue Distribution, and Safety Profile.

  2026cites this paper
• Next-generation T cell engagers in oncology: Pharmacologic evolution from bispecific to trispecific antibodies

  2025cites this paper
• Optimizing efficacy and safety of T cell bispecific antibodies: the interdependence of CD3 and tumor antigen binder affinities in FOLR1 and CEACAM5 2 + 1 TCBs

  2025cites this paper
• Disulfide-stabilized diabodies enable near-atomic cryo-EM imaging of small proteins: A case study of the bacterial Na+/citrate symporter CitS.

  2025cites this paper
• Development and clinical trial of M701, an Anti-EpCAM × Anti-CD3 bispecific antibody: a targeted intraperitoneal therapy for malignant ascites stemming from advanced solid tumors

  2025cites this paper
• T-cell engager toxicity in clinical phase trials; A systematic review and meta-analysis.

  2025cites this paper
• Depletion-restitution therapy of autoimmune rheumatic diseases. Part 2. Perspectives on bispecific antibodies

  2025cites this paper
• Bispecific antibodies: unleashing a new era in oncology treatment

  2025cites this paper
• How useful are 3-month repeat-dose toxicology studies for the development of T cell engagers for oncology indications?

  2025cites this paper
• New advances on the interaction between internal and external factors in the tumor microenvironment of solid tumors

  2025cites this paper
• Chronic antigen stimulation in melanoma induces T cell exhaustion and limits efficacy of T cell bispecific therapies

  2025cites this paper
• Application and future prospects of bispecific antibodies in the treatment of non-small cell lung cancer

  2025cites this paper
• The Evolving Landscape of Antibody-Based Cancer Therapies: From Monospecific to Multi-Specific and Beyond.

  2025cites this paper
• Recent advancements in aptamer-mediated theranostics in the management of hematological disorders.

  2025cites this paper
• Fifty years of monoclonals: the past, present and future of antibody therapeutics

  2025cites this paper
• The Evolving Applications of Bispecific Antibodies: Reaping the Harvest of Early Sowing and Planting New Seeds

  2024cites this paper
• The present and future of bispecific antibodies for cancer therapy

  2024cites this paper
• A Brief Chronicle of Antibody Research and Technological Advances

  2024cites this paper
• Recent Advances in Drug Delivery Strategies for High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: A Brief Review from 2018 to 2024

  2024cites this paper
• Exploring the biomarkers and potential therapeutic drugs for sepsis via integrated bioinformatic analysis

  2024cites this paper
• Bispecific therapeutics: a state-of-the-art review on the combination of immune checkpoint ‎inhibition with costimulatory and non-checkpoint targeted therapy

  2024cites this paper
• Mechanism-Driven Design of Multispecific Antibodies for Targeted Disease Treatment.

  2024cites this paper
• Immunocytes interact directly with cancer cells in the tumor microenvironment: one coin with two sides and future perspectives

  2024cites this paper
• Activating adaptive immunity by bispecific, T-cell engager antibodies bridging infected and immune-effector cells is a promising novel therapy for chronic hepatitis B.

  2024cites this paper
• Clinical Progresses and Challenges of Bispecific Antibodies for the Treatment of Solid Tumors

  2024cites this paper
• Warming-up the immune cell engagers (ICEs) era in breast cancer: state of the art and future directions.

  2024cites this paper
• Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer

  2024cites this paper
• Niche-specific control of tissue function by regulatory T cells-Current challenges and perspectives for targeting metabolic disease.

  2024cites this paper
• Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy?

  2024cites this paper
• A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy

  2024cites this paper
• Bispecific Nanobody-Aptamer Conjugates for Enhanced Cancer Therapy in Solid Tumors.

  2024cites this paper
• Crosstalk between colorectal CSCs and immune cells in tumorigenesis, and strategies for targeting colorectal CSCs

  2024cites this paper
• A pivotal decade for bispecific antibodies?

  2024cites this paper
• Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment

  2023cites this paper
• Bispecific antibodies and its applications: a novel approach for targeting SARS-Cov-2

  2023cites this paper
• Multi-targeted immunotherapeutics to treat B cell malignancies.

  2023cites this paper
• Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies

  2023cites this paper
• Clinical efficacy and safety of bispecific antibodies for the treatment of solid tumors: a systematic review and meta-analysis

  2023cites this paper
• Deciphering Common Traits of Breast and Ovarian Cancer Stem Cells and Possible Therapeutic Approaches

  2023cites this paper
• Cancer Stem Cells: Recent Insights and Therapies.

  2023cites this paper
• Immunotargeting of Cancer Stem Cells

  2023cites this paper
• Peritoneal Metastasis: A Dilemma and Challenge in the Treatment of Metastatic Colorectal Cancer

  2023cites this paper
• Current understanding of cancer stem cells: Immune evasion and targeted immunotherapy in gastrointestinal malignancies

  2023cites this paper
• Suppression of MUC1-Overexpressing Tumors by a Novel MUC1/CD3 Bispecific Antibody

  2023cites this paper
• Epithelial cell adhesion molecule-targeting designed ankyrin repeat protein-toxin fusion Ec1-LoPE exhibits potent cytotoxic action in prostate cancer cells

  2022cites this paper
• Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology

  2022cites this paper
• Immunosenescence, inflammaging, and cancer immunotherapy efficacy

  2022cites this paper
• Emerging new therapeutic antibody derivatives for cancer treatment

  2022cites this paper
• T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities

  2022cites this paper
• T-cell engaging bispecific antibody therapy

  2022cites this paper
• Visualization of epithelial cell adhesion molecule-expressing renal cell carcinoma xenografts using designed ankyrin repeat protein Ec1 labelled with 99mTc and 125I

  2022cites this paper
• Anti-cancer therapeutic strategies based on HGF/MET, EpCAM, and tumor-stromal cross talk

  2022cites this paper
• Shortened Hinge Design of Fab x sdAb-Fc Bispecific Antibodies Enhances Redirected T-Cell Killing of Tumor Cells

  2022cites this paper
• Current landscape and future directions of bispecific antibodies in cancer immunotherapy

  2022cites this paper
• Biologics in rectal cancer

  2022cites this paper
• Oncolytic adenovirus inhibits malignant ascites of advanced ovarian cancer by reprogramming the ascitic immune microenvironment

  2021cites this paper
• Bispecific antibodies in colorectal cancer therapy: recent insights and emerging concepts.

  2021cites this paper
• Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma

  2021cites this paper
• Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning

  2021cites this paper
• Cytokine Release Syndrome By T-cell–Redirecting Therapies: Can We Predict and Modulate Patient Risk?

  2021cites this paper
• An optimal antitumor response by a novel CEA/CD3 bispecific antibody for colorectal cancers

  2021cites this paper
• Novel Immune Engagers and Cellular Therapies for Metastatic Castration-Resistant Prostate Cancer: Do we take a BiTe or ride BiKEs, TriKEs, and CARs?

  2021cites this paper
• Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model

  2021cites this paper
• Recent Advances in the Molecular Design and Applications of Multispecific Biotherapeutics

  2021cites this paper
• First time intravesically administered trifunctional antibody catumaxomab in patients with recurrent non-muscle invasive bladder cancer indicates high tolerability and local immunological activity

  2021cites this paper
• The Cancer Stem Cell Niche in Ovarian Cancer and Its Impact on Immune Surveillance

  2021cites this paper
• The Effects of Lentivirus-Mediated Gene Silencing of RARβ on the Stemness Capability of Non-Small Cell Lung Cancer

  2021cites this paper
• Engineered Bifunctional Proteins for Targeted Cancer Therapy: Prospects and Challenges

  2021cites this paper
• Ternary Polypeptide Nanoparticles with Improved Encapsulation, Sustained Release, and Enhanced In Vitro Efficacy of Carfilzomib

  2020cites this paper
• Immunotherapies in ovarian cancer

  2020cites this paper
• Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy

  2020cites this paper
• Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity

  2020cites this paper
• The Role of Nanofiltration in the Pathogen Safety of Biologicals: An Update

  2020cites this paper
• Selection for Anti-transferrin Receptor Bispecific T-cell Engager in Different Molecular Formats

  2020cites this paper
• In vitro toxicological support to establish specification limit for anti-CD3 monospecific impurity in a bispecific T cell engager drug, ERY974.

  2020cites this paper
• Bispecific Antibodies and Antibody–Drug Conjugates for Cancer Therapy: Technological Considerations

  2020cites this paper
• Development of bispecific antibodies in China: overview and prospects

  2020cites this paper
• Bispecific Antibodies: Progress and Application

  2020cites this paper
• Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma

  2020cites this paper
• Immunotherapy Advances for Epithelial Ovarian Cancer

  2020cites this paper
• A review of bispecific antibodies and antibody constructs in oncology and clinical challenges.

  2019cites this paper
• T-cell Activating Tribodies as a Novel Approach for Efficient Killing of ErbB2-positive Cancer Cells

  2019cites this paper
• Approval of First CAR-Ts: Have we Solved all Hurdles for ATMPs?

  2019cites this paper
• Structural diversity and flexibility of diabodies.

  2019cites this paper
• Passive Monoclonal and Polyclonal Antibody Therapies

  2019cites this paper
• Targeting Membrane Receptors of Ovarian Cancer Cells for Therapy.

  2019cites this paper
• Ovarian cancer stem cells and targeted therapy

  2019cites this paper
• Single-step Protein A and Protein G avidity purification methods to support bispecific antibody discovery and development

  2019cites this paper
• Fluorescence-guided tumor detection with a novel anti-EpCAM targeted antibody fragment: Preclinical validation.

  2019cites this paper
• A T-cell–engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer

  2019cites this paper
• Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: Success and Limitations.

  2019cites this paper
• Producing and prospects for the use of bispecific antibodies for the treatment of cancer

  2019cites this paper
• MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis

  2019cites this paper
• Influence of the bispecific antibody IgG subclass on T cell redirection

  2019cites this paper
• T cell-redirecting bispecific antibodies in cancer immunotherapy: recent advances

  2019influential citation
• Daily ascending dosing in cynomolgus monkeys to mitigate cytokine release syndrome induced by ERY22, surrogate for T-cell redirecting bispecific antibody ERY974 for cancer immunotherapy.

  2019cites this paper
• Bispecific antibodies: Potential immunotherapies for HIV treatment.

  2019cites this paper
• NK Cell-Based Immunotherapy in Cancer Metastasis

  2018cites this paper
• The bispecific anti-CD3 × anti-CD155 antibody mediates T cell immunotherapy for human prostate cancer

  2018cites this paper
• Concise Review: Aggressive Colorectal Cancer: Role of Epithelial Cell Adhesion Molecule in Cancer Stem Cells and Epithelial‐to‐Mesenchymal Transition

  2018cites this paper